Joy Schechtman

2.4k total citations · 1 hit paper
17 papers, 1.7k citations indexed

About

Joy Schechtman is a scholar working on Rheumatology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Joy Schechtman has authored 17 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 6 papers in Genetics and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Joy Schechtman's work include Rheumatoid Arthritis Research and Therapies (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Joy Schechtman is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Joy Schechtman collaborates with scholars based in United States, Sweden and Germany. Joy Schechtman's co-authors include Roy Fleischmann, Ronald van Vollenhoven, Artur Racewicz, Arthur Kavanaugh, Anna Filipowicz‐Sosnowska, E. Hessey, Sunil Agarwal, Nicole F. Li, Paul Emery and L Szczepański and has published in prestigious journals such as Annals of Internal Medicine, Annals of the Rheumatic Diseases and Inflammatory Bowel Diseases.

In The Last Decade

Joy Schechtman

16 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

2006 783 citations Paul Emery, Roy Fleischmann et al. Arthritis & Rheumatism profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Joy Schechtman	1.1k	533	421	405	360	17	1.7k
Jonathan S. Coblyn	1.2k 1.1×	443 0.8×	466 1.1×	265 0.7×	368 1.0×	34	2.1k
M. Lange	1.7k 1.6×	574 1.1×	941 2.2×	261 0.6×	277 0.8×	7	2.2k
Tim Shaw	1.3k 1.2×	902 1.7×	463 1.1×	640 1.6×	576 1.6×	16	2.5k
Y P M Goekoop-Ruiterman	2.4k 2.2×	399 0.7×	880 2.1×	225 0.6×	485 1.3×	30	2.6k
E. Hessey	1.7k 1.6×	732 1.4×	650 1.5×	615 1.5×	710 2.0×	8	2.4k
J.H.L.M. van Groenendael	1.9k 1.7×	324 0.6×	744 1.8×	175 0.4×	406 1.1×	22	2.1k
Joel Kremer	1.1k 1.0×	464 0.9×	534 1.3×	190 0.5×	306 0.8×	12	1.5k
Koichi Amano	1.4k 1.3×	477 0.9×	431 1.0×	115 0.3×	524 1.5×	133	2.2k
A. Gerards	1.7k 1.6×	336 0.6×	749 1.8×	148 0.4×	383 1.1×	29	2.0k
James D. McKay	1.4k 1.3×	908 1.7×	316 0.8×	654 1.6×	181 0.5×	13	1.7k

Countries citing papers authored by Joy Schechtman

Since Specialization

Citations

This map shows the geographic impact of Joy Schechtman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Schechtman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Schechtman more than expected).

Fields of papers citing papers by Joy Schechtman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Schechtman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Schechtman. The network helps show where Joy Schechtman may publish in the future.

Co-authorship network of co-authors of Joy Schechtman

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Schechtman. A scholar is included among the top collaborators of Joy Schechtman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Schechtman. Joy Schechtman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Schechtman, Joy, Alan Kivitz, Natalie J. Shiff, et al.. (2023). Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study. BMC Rheumatology. 7(1). 5–5. 1 indexed citations

Schechtman, Joy, et al.. (2021). POS0590 SAFETY AND EFFICACY OF BIOLOGICS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL WORLD STUDY: USE OF INTRAVENOUS GOLIMUMAB AND INFLIXIMAB IN ADULTS WITH RHEUMATOID ARTHRITIS ≥65 YEARS OF AGE. Annals of the Rheumatic Diseases. 80. 527–528. 11 indexed citations

Özyürekoğlu, Tuna, Anton Khlopas, Michael A. Mont, et al.. (2018). A Pulsed Electrical Joint Stimulator for the Treatment of Osteoarthritis of the Hand and Wrist. Orthopedics. 41(4). e550–e556. 1 indexed citations

Kivitz, Alan, Joy Schechtman, Michele Texter, et al.. (2014). Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial. The Journal of Rheumatology. 41(4). 648–657. 51 indexed citations

Kivitz, Alan, Joy Schechtman, Michele Texter, Andreas Fichtner, & Elliot Chartash. (2014). P-146 Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients Receiving Certolizumab Pegol. Inflammatory Bowel Diseases. 20(2). E8–E8.

Hungerford, David S., et al.. (2013). Synergistic effect of using a transcutaneous electrical joint stimulator and an unloading brace in treating osteoarthritis of the knee.. PubMed. 42(10). 456–63. 3 indexed citations

Huffstutter, J. Eugene, James C. Taylor, Joy Schechtman, et al.. (2011). Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the Phase III FEATURE trial. International Journal of Clinical Rheumatology. 6(6). 689–696. 5 indexed citations

Deodhar, Atul, Robin K. Dore, David R. Mandel, et al.. (2010). Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care & Research. 62(4). 569–574. 96 indexed citations

Genovese, Mark C., Jeffrey Kaine, Mitchell B. Lowenstein, et al.. (2008). Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study. Arthritis & Rheumatism. 58(9). 2652–2661. 157 indexed citations

10.

Schechtman, Joy, et al.. (2007). The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.. PubMed. 25(1). 40–6. 115 indexed citations

11.

Emery, Paul, Roy Fleischmann, Anna Filipowicz‐Sosnowska, et al.. (2006). The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis & Rheumatism. 54(5). 1390–1400. 783 indexed citations breakdown →

12.

Vollenhoven, Ronald van, Joy Schechtman, R Fleischmann, et al.. (2005). Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study. Queensland's institutional digital repository (The University of Queensland). 52(9). 12 indexed citations

13.

Tesser, John, Roy Fleischmann, Robin K. Dore, et al.. (2004). Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.. PubMed. 31(4). 649–54. 29 indexed citations

14.

Schiff, Michael, John Tesser, Roy Fleischmann, et al.. (2004). The safety of anakinra in high‐risk patients with active rheumatoid arthritis: Six‐month observations of patients with comorbid conditions. Arthritis & Rheumatism. 50(6). 1752–1760. 66 indexed citations

15.

Fleischmann, Roy, Joy Schechtman, M. Händel, et al.. (2003). Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial. Arthritis & Rheumatism. 48(4). 927–934. 292 indexed citations

16.

Lisse, Jeffrey, Gunnar Johansson, Joy Schechtman, et al.. (2003). Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis. Annals of Internal Medicine. 139(7). 539–546. 102 indexed citations

17.

Johansson, Gunnar, et al.. (2001). SAT0096 Gastrointestinal tolerability in primary care patients treated with naproxen or rofecoxib for osteoarthritis (oa): the advantage trial. Annals of the Rheumatic Diseases. 60. A187–A187. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact